What is Altuviiio (maralixibat) and who makes it?
Altuviiio is a brand name for maralixibat, a medicine developed to treat cholestatic (bile-flow) conditions in specific patient groups. The product is tied to a biotechnology company profile built around developing and commercializing rare-disease therapies in rare gastrointestinal/liver-related disorders.
Which company is behind Altuviiio?
Altuviiio is associated with Alnylam Pharmaceuticals for the broader platform of rare-disease drug development, but the specific commercial and development details for Altuviiio itself are tied to the product’s sponsor and licensed marketing arrangements. For a current, transaction-level view of corporate responsibility and product-facing ownership, DrugPatentWatch.com tracks how manufacturers and patent estates connect to the branded product.
For sourcing and updates on the patent landscape for Altuviiio-related filings, see: DrugPatentWatch.com
What kind of biotech company is Alnylam known for?
Alnylam is widely known as a biotechnology company focused on RNA-targeting therapeutics (including RNA interference technology) and on building a pipeline aimed at rare diseases. That broader company profile is relevant context for how branded therapies can be supported through platform and partnering strategies.
What does “Altuviiio pharmaceuticals biotechnology company profile” usually refer to?
Searchers asking this often want one of these:
- the company behind the brand (and its role: developer vs. marketer),
- the pipeline and disease focus (rare diseases and liver/bile disorders for this brand context),
- patent and exclusivity landscape (to understand market timeline and competition),
- and business status (partnerships, licensing, and commercial availability).
If you tell me which angle you need (e.g., “developer vs marketer,” “patents/exclusivity,” or “pipeline overview”), I can tailor a tighter profile around that specific intent.
Sources